146 related articles for article (PubMed ID: 22511598)
21. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma.
Zhang S; Li L; Lin JY; Lin H
World J Gastroenterol; 2003 May; 9(5):899-904. PubMed ID: 12717827
[TBL] [Abstract][Full Text] [Related]
22. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival.
Nakopoulou L; Tsirmpa I; Alexandrou P; Louvrou A; Ampela C; Markaki S; Davaris PS
Breast Cancer Res Treat; 2003 Jan; 77(2):145-55. PubMed ID: 12602913
[TBL] [Abstract][Full Text] [Related]
23. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis.
Sutinen M; Kainulainen T; Hurskainen T; Vesterlund E; Alexander JP; Overall CM; Sorsa T; Salo T
Br J Cancer; 1998 Jun; 77(12):2239-45. PubMed ID: 9649139
[TBL] [Abstract][Full Text] [Related]
24. Role of tissue inhibitors of metalloproteinases (TIMPs) in colorectal carcinoma.
Joo YE; Seo KS; Kim J; Kim HS; Rew JS; Park CS; Kim SJ
J Korean Med Sci; 1999 Aug; 14(4):417-23. PubMed ID: 10485622
[TBL] [Abstract][Full Text] [Related]
25. Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary.
Okamoto T; Niu R; Yamada S
Mol Hum Reprod; 2003 Oct; 9(10):569-75. PubMed ID: 12970394
[TBL] [Abstract][Full Text] [Related]
26. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
[TBL] [Abstract][Full Text] [Related]
28. Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer.
Nakopoulou L; Katsarou S; Giannopoulou I; Alexandrou P; Tsirmpa I; Panayotopoulou E; Mavrommatis J; Keramopoulos A
Mod Pathol; 2002 Jan; 15(1):26-34. PubMed ID: 11796838
[TBL] [Abstract][Full Text] [Related]
29. Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.
Steffensen KD; Waldstrøm M; Christensen RK; Bartels A; Brünner N; Jakobsen A
BMC Cancer; 2010 May; 10():185. PubMed ID: 20459644
[TBL] [Abstract][Full Text] [Related]
30. Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer.
Pradhan-Palikhe P; Vesterinen T; Tarkkanen J; Leivo I; Sorsa T; Salo T; Mattila PS
Oral Oncol; 2010 Jul; 46(7):514-8. PubMed ID: 20371206
[TBL] [Abstract][Full Text] [Related]
31. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.
Zhang B; Cao X; Liu Y; Cao W; Zhang F; Zhang S; Li H; Ning L; Fu L; Niu Y; Niu R; Sun B; Hao X
BMC Cancer; 2008 Mar; 8():83. PubMed ID: 18373849
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer.
Sharma R; Chattopadhyay TK; Mathur M; Ralhan R
Oncology; 2004; 67(3-4):300-9. PubMed ID: 15557792
[TBL] [Abstract][Full Text] [Related]
33. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
[TBL] [Abstract][Full Text] [Related]
35. High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy.
Zhu D; Zha X; Hu M; Tao A; Zhou H; Zhou X; Sun Y
Med Oncol; 2012 Dec; 29(5):3207-15. PubMed ID: 22544540
[TBL] [Abstract][Full Text] [Related]
36. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
[TBL] [Abstract][Full Text] [Related]
37. [Regulation of matrix-degrading enzymes in gynecologic cancer tissues and cells].
Kikkawa F
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):618-22. PubMed ID: 8808829
[TBL] [Abstract][Full Text] [Related]
38. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma.
Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Ben-Baruch G; Nesland JM; Reich R
Mol Cell Endocrinol; 2002 Feb; 187(1-2):39-45. PubMed ID: 11988310
[TBL] [Abstract][Full Text] [Related]
39. [Matrix metalloproteinase 2 and 9 as the factor of head and neck tumor metastasis].
Kondakova IV; Klisho EV; savenkova OV; Kakurina GV; Choĭnzonov EL; Shishkin DA; Mukhamedov MP
Biomed Khim; 2008; 54(5):555-60. PubMed ID: 19105397
[TBL] [Abstract][Full Text] [Related]
40. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
